Luteal phase defects in assisted reproduction: the role of luteal phase supplementation.
Data from literature show that whereas in non-GnRH-a controlled ovarian hyperstimulation cycles luteal phase supplementation is not crucial, its use in GnRH-a/gonadotropins protocols seems to lead to a definite reduction of the negative effects of such drugs. The most important side effect of the hCG use as luteal support is the increased rate of the ovarian hyperstimulation syndrome (OHSS). Therefore its use should be reserved for very selected patients, for those subjects with preovulatory levels of E2 < 2500 pg/ml. As regard the use of progesterone, most authors agree that it has less efficacy than hCG but this depends on the administration route.
Capitanio
G L
GL
Department of Obstetrics and Gynecology, University of Chieti, Italy.
Ubaldi
F
F
Giannini
P
P
Croce
S
S
D006063:Chorionic Gonadotropin / Q000009:adverse effects / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D015181:Gamete Intrafallopian Transfer; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects* / Q000378:metabolism; D008596:Menotropins / Q000627:therapeutic use; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods*; D011247:Pregnancy; D011374:Progesterone / Q000096:biosynthesis / Q000627:therapeutic use
D006063:Chorionic Gonadotropin; D002996:Clomiphene; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins